Biogen appoints Michel Vounatsos executive vice president, chief commercial officer
pharmafile | March 30, 2016 | Appointment | Research and Development, Sales and Marketing |
Biogen has appointed Michel Vounatsos as executive vice president and chief commercial officer, from April 18, 2016.
Vounatsos will oversee the development and execution of Biogen’s global commercial strategy, with a focus on continuing the growth of Biogen’s product portfolio and the developing the commercial infrastructure and approach to support the company’s key pipeline assets. He will report to George Scangos, chief executive officer, and will be a member of the Biogen management team.
“Michel is a sophisticated global business leader who brings a track record of commercial success and creativity to Biogen,” says Dr Scangos. “As the complexity of our business and the expectations of our stakeholders accelerate, Michel will play a critical role in driving our near-term growth while helping prepare our organisation to support our increasingly robust and diverse pipeline.”
Vounatsos joins Biogen after a 20 year career at Merck, where he most recently served as president, Primary Care Business Line and Merck Customer Centricity. Prior to this role, he held leadership positions at Merck across Europe and in China. Mr. Vounatsos attended the Universite Victor Segalen, Bordeaux II, in France, receiving his C.S.C.T. certificate in Medicine. He received his M.B.A. from the HEC School of Management in Paris.
“I am excited to work with my new colleagues to deliver on the unique promise of the Biogen pipeline as we seek to transform the lives of patients with neurodegenerative and rare diseases around the world,” says Vounatsos. “As I move to Biogen, I am grateful to the team at Merck for the tremendous opportunities I have had over the past two decades.”
